These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 37485697)
21. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Valle LF; Lehrer EJ; Markovic D; Elashoff D; Levin-Epstein R; Karnes RJ; Reiter RE; Rettig M; Calais J; Nickols NG; Dess RT; Spratt DE; Steinberg ML; Nguyen PL; Davis BJ; Zaorsky NG; Kishan AU Eur Urol; 2021 Sep; 80(3):280-292. PubMed ID: 33309278 [TBL] [Abstract][Full Text] [Related]
22. Extreme hypofractionated stereotactic radiotherapy for elderly prostate cancer patients: side effects preliminary analysis of a phase II trial. Gregucci F; Carbonara R; Surgo A; Ciliberti MP; Curci D; Ciocia A; Branà L; Ludovico GM; Scarcia M; Portoghese F; Caliandro M; Ludovico E; Paulicelli E; Di Guglielmo FC; Bonaparte I; Fiorentino A Radiol Med; 2023 Apr; 128(4):501-508. PubMed ID: 36952115 [TBL] [Abstract][Full Text] [Related]
23. Linac-based SBRT as a feasible salvage option for local recurrences in previously irradiated prostate cancer. Cuccia F; Nicosia L; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Vitale C; Corradini S; Ruggieri R; Alongi F Strahlenther Onkol; 2020 Jul; 196(7):628-636. PubMed ID: 32399638 [TBL] [Abstract][Full Text] [Related]
24. Time-Driven Activity-Based Costing of CT-Guided vs MR-Guided Prostate SBRT. Parikh NR; Clark MA; Patel P; Kafka-Peterson K; Zaide L; Ma TM; Steinberg ML; Cao M; Raldow AC; Lamb J; Kishan AU Appl Radiat Oncol; 2021 Sep; 10(3):33-40. PubMed ID: 34671700 [TBL] [Abstract][Full Text] [Related]
25. Stereotactic Radiotherapy for Lesions Detected via Pan J; Wei Y; Zhang T; Liu C; Hu X; Zhao J; Gan H; Liu W; Zhu B; Wu J; Wang B; Song S; Ye D; Zhu Y Eur Urol Oncol; 2022 Aug; 5(4):420-427. PubMed ID: 35304107 [TBL] [Abstract][Full Text] [Related]
26. Rectal spacer hydrogel in 1.5T MR-guided and daily adapted SBRT for prostate cancer: dosimetric analysis and preliminary patient-reported outcomes. Alongi F; Rigo M; Figlia V; Cuccia F; Giaj-Levra N; Nicosia L; Ricchetti F; Vitale C; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Mazzola R Br J Radiol; 2021 Jan; 94(1117):20200848. PubMed ID: 33095659 [TBL] [Abstract][Full Text] [Related]
27. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial. Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270 [TBL] [Abstract][Full Text] [Related]
28. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy. Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240 [TBL] [Abstract][Full Text] [Related]
29. Stereotactic Body Radiation Therapy for the Curative Treatment of Prostate Cancer in Ultralarge (≥100 cc) Glands. Hurwitz JC; Haas J; Mendez C; Sanchez A; Santos VF; Akerman M; Carpenter T; Tam M; Katz A; Corcoran A; Mahadevan A; Taneja SS; Lepor H; Lischalk JW Pract Radiat Oncol; 2024; 14(3):241-251. PubMed ID: 37984713 [TBL] [Abstract][Full Text] [Related]
30. Phase II study of stereotactic body radiotherapy with hydrogel spacer for prostate cancer: acute toxicity and propensity score-matched comparison. Ogita M; Yamashita H; Nozawa Y; Ozaki S; Sawayanagi S; Ohta T; Nakagawa K Radiat Oncol; 2021 Jun; 16(1):107. PubMed ID: 34118956 [TBL] [Abstract][Full Text] [Related]
31. Stereotactic body radiation therapy for prostate cancer: systematic review and meta-analysis of prospective trials. Cushman TR; Verma V; Khairnar R; Levy J; Simone CB; Mishra MV Oncotarget; 2019 Sep; 10(54):5660-5668. PubMed ID: 31608141 [No Abstract] [Full Text] [Related]
32. Acute side effects after definitive stereotactic body radiation therapy (SBRT) for patients with clinically localized or locally advanced prostate cancer: a single institution prospective study. Jorgo K; Polgar C; Stelczer G; Major T; Gesztesi L; Agoston P Radiol Oncol; 2021 Jul; 55(4):474-481. PubMed ID: 34253001 [TBL] [Abstract][Full Text] [Related]
33. State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature. Le Guevelou J; Bosetti DG; Castronovo F; Angrisani A; de Crevoisier R; Zilli T World J Urol; 2023 Nov; 41(11):3287-3299. PubMed ID: 37668718 [TBL] [Abstract][Full Text] [Related]
34. Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes. Hwang ME; Mayeda M; Liz M; Goode-Marshall B; Gonzalez L; Elliston CD; Spina CS; Padilla OA; Wenske S; Deutsch I Radiat Oncol; 2019 Aug; 14(1):136. PubMed ID: 31375119 [TBL] [Abstract][Full Text] [Related]
36. High-Dose Robotic Stereotactic Body Radiotherapy in the Treatment of Patients With Prostate Cancer: Preliminary Results in 26 Patients. Pontoriero A; Iatì G; Mondello S; Midili F; Siragusa C; Brogna A; Ielo I; Anastasi G; Magno C; Pergolizzi S; De Renzis C Technol Cancer Res Treat; 2016 Feb; 15(1):179-85. PubMed ID: 25586517 [TBL] [Abstract][Full Text] [Related]
37. A pilot study of stereotactic body radiotherapy combined with pelvic radiotherapy and GTVp boost based on multiparameter magnetic resonance image in patients with high-risk prostate cancer. Wang F; Yao J; Chen J; Zeng H; Wang X Medicine (Baltimore); 2023 Sep; 102(39):e35260. PubMed ID: 37773877 [TBL] [Abstract][Full Text] [Related]
38. Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients. Nicosia L; Mazzola R; Rigo M; Figlia V; Giaj-Levra N; Napoli G; Ricchetti F; Corradini S; Ruggieri R; Alongi F J Cancer Res Clin Oncol; 2019 Oct; 145(10):2547-2554. PubMed ID: 31324979 [TBL] [Abstract][Full Text] [Related]
39. Impact of Interfractional Bladder and Trigone Displacement and Deformation on Radiation Exposure and Subsequent Acute Genitourinary Toxicity: A Post Hoc Analysis of Patients Treated with Magnetic Resonance Imaging-Guided Prostate Stereotactic Body Radiation Therapy in a Phase 3 Randomized Trial. Neilsen BK; Ma TM; Akingbemi WO; Neylon J; Casado MC; Sharma S; Sheng K; Ruan D; Low DA; Yang Y; Valle LF; Steinberg ML; Lamb JM; Cao M; Kishan AU Int J Radiat Oncol Biol Phys; 2024 Mar; 118(4):986-997. PubMed ID: 37871887 [TBL] [Abstract][Full Text] [Related]
40. 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment. Alongi F; Rigo M; Figlia V; Cuccia F; Giaj-Levra N; Nicosia L; Ricchetti F; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Mazzola R Radiat Oncol; 2020 Mar; 15(1):69. PubMed ID: 32248826 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]